Today: 20 May 2026
Browse Category

NASDAQ:CABA 31 October 2025 - 4 May 2026

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio shares surged 32% after the company reported early results from its cell-therapy trial and priced a $150 million stock offering with participation from Eli Lilly and others. Two of four pemphigus vulgaris patients showed clinical activity with rese-cel, its experimental CAR-T therapy. The company expects to fund operations into mid-2027. New data will be presented at the ASGCT meeting on May 14.
4 May 2026
····
Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape

Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape

Cabaletta Bio shares rose about 11% premarket Thursday after insider-buying reports, trading at $2.60 versus Wednesday’s $2.34 close. CEO Steven Nichtberger bought 45,000 shares Jan. 21, with other executives and directors also purchasing stock, SEC filings show. Trading volume Wednesday hit 2.09 million shares. The company is developing an experimental CD19 CAR-T therapy for autoimmune diseases.
22 January 2026
·
Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Cabaletta Bio shares surged up to 46% on Oct. 31, closing at $3.61 after strong CAR-T therapy data, with trading volume hitting 35.7 million shares. Phase 1/2 results showed major improvements in myositis and systemic sclerosis, and durable lupus nephritis remissions. The company remains pre-revenue, holding $194.7 million cash as of June 30. Wall Street analysts mostly rate CABA a “Buy,” with targets averaging $13–15.
31 October 2025
··

Stock Market Today

  • 4 Singapore Stocks Poised for Higher Dividends in 2026
    May 20, 2026, 6:15 AM EDT. Investors eye dividend growth over yield, seeking stocks that steadily raise payouts backed by strong earnings and cash flow. Singapore's ST Engineering reported a 21% rise in net profit and increased dividends, retaining room for future raises. Frasers Centrepoint Trust saw distributions climb 13.6% amid cash flow expansion and disciplined debt management. Singapore Exchange Limited shows promise through balance sheet strength and operating momentum. These stocks highlight durable fundamentals supporting potential dividend hikes in 2026, appealing to investors favoring income growth and inflation protection.

Latest articles

Bolt CEO Axed HR, Then Said the Problems Vanished. Why It Matters Now

Bolt CEO Axed HR, Then Said the Problems Vanished. Why It Matters Now

20 May 2026
Bolt CEO Ryan Breslow defended cutting the company’s HR department at Fortune’s Workplace Innovation Summit, saying it had “created problems that didn’t exist.” The move follows Bolt’s April layoffs of about 30% of staff as it pivots to AI and a consumer finance app. Breslow said Bolt is “back in startup mode” and replaced HR with a smaller people operations team. Bolt was once valued at $11 billion.
San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

20 May 2026
OCI Energy and CPS Energy have begun building a 120-megawatt battery storage facility in southeastern Bexar County, aiming for commercial operation in 2027. The project follows a rise in average outage duration for CPS Energy customers to 75.38 minutes in 2025. OCI will own the facility, with CPS holding operational control. ING is financing construction, and LG Energy Solution Vertech is supplying batteries.
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

20 May 2026
Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
Go toTop